AP
IONS icon

Aspect Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Aspect Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$1.5K – 721
2026
Q1 		$1.5K Hold
20
– – ﹤0.01% 546
2025
Q4 		$1.58K Buy
+20
New +$1.51K ﹤0.01% 582

Other funds holding IONS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
WMA
West Michigan Advisors Holland, Michigan $455M AUM 31.82% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aspect Partners's IONS Position: Q2 2026 in Review

Aspect Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 20 shares — an estimated $1.5K sold.

Aspect Partners first reported a position in IONS in Q4 2025 and held it in 2 quarters. The position peaked at $1.58K in Q4 2025. 84 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Aspect Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aspect Partners sold 20 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.5K.
  • Aspect Partners first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Aspect Partners's Ionis Pharmaceuticals position peaked at $1.58K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.